Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1

Interventions

Imatinib Mesylate 9fludarabine 5Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Cyclophosphamide 5Busulfan 5ponatinib 4nilotinib 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 3Bone Marrow Transplantation 3venetoclax 2thymoglobulin 2asciminib 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Dasatinib 2Behavior Therapy 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2zileuton 1spartalizumab 1sabatolimab 1nicotinamide-beta-riboside 1methanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × zileuton × Myeloid × Clear all
NCT02047149 2016-09-30

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡